In fact, in a recent study, LYZL1 gene expression was found to vary according to the expression of two biomarkers that have been suggested to be involved in ovarian cancer paclitaxel resistance (i.e., low MAD2/high TLR4 expression: increased expression of LYZL1; high MAD2/low TLR4 expression: decreased expression of LYZL1) [63]. Here, TLR4 is linked to ovarian cancer.